Published in PLoS One on January 30, 2014
To be or not IIb: a multi-step process for Epstein-Barr virus latency establishment and consequences for B cell tumorigenesis. PLoS Pathog (2015) 0.79
Metabolic stress is a barrier to Epstein-Barr virus-mediated B-cell immortalization. Proc Natl Acad Sci U S A (2016) 0.79
Take your PIKK: tumour viruses and DNA damage response pathways. Philos Trans R Soc Lond B Biol Sci (2017) 0.76
Guizhi Fuling Wan as a novel agent for intravesical treatment for bladder cancer in mouse model. Mol Med (2016) 0.75
Activation of ATR-Chk1 pathway facilitates EBV-mediated transformation of primary tonsillar B-cells. Oncotarget (2016) 0.75
Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application. J Transl Med (2017) 0.75
Recent advances in understanding Epstein-Barr virus. F1000Res (2017) 0.75
Limited nucleotide pools restrict Epstein-Barr virus-mediated B-cell immortalization. Oncogenesis (2017) 0.75
Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell (2000) 20.83
Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature (2005) 14.65
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature (2006) 11.76
An oncogene-induced DNA damage model for cancer development. Science (2008) 11.60
Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature (2006) 11.18
DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet (2001) 10.77
Involvement of the bcl-2 gene in human follicular lymphoma. Science (1985) 8.19
DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science (2000) 7.85
Oncogenically active MYD88 mutations in human lymphoma. Nature (2010) 7.34
DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene (2007) 3.67
Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev (2009) 3.56
Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol (2002) 3.08
Cellular origin of human B-cell lymphomas. N Engl J Med (1999) 2.91
Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat Immunol (2007) 2.90
Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. J Clin Invest (2008) 2.83
Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity (1995) 2.74
Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer. Nat Cell Biol (2011) 2.69
Control systems and decision making for antibody production. Nat Immunol (2010) 2.60
Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol (2000) 2.59
DNA-SCARS: distinct nuclear structures that sustain damage-induced senescence growth arrest and inflammatory cytokine secretion. J Cell Sci (2010) 2.34
An ATM/Chk2-mediated DNA damage-responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells. Cell Host Microbe (2010) 2.23
Immunoglobulin switch transcript production in vivo related to the site and time of antigen-specific B cell activation. J Exp Med (1996) 2.18
Evidence from the generation of immunoglobulin G-secreting cells that stochastic mechanisms regulate lymphocyte differentiation. Nat Immunol (2003) 2.11
Epstein-Barr virus provides a new paradigm: a requirement for the immediate inhibition of apoptosis. PLoS Biol (2005) 2.08
Epstein-barr virus transformation: involvement of latent membrane protein 1-mediated activation of NF-kappaB. Oncogene (1999) 1.69
Toll-like receptor driven B cell activation in the induction of systemic autoimmunity. Semin Immunol (2011) 1.67
B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev (2010) 1.60
A model of immune regulation as a consequence of randomized lymphocyte division and death times. Proc Natl Acad Sci U S A (2007) 1.57
TLR9 activation is defective in common variable immune deficiency. J Immunol (2006) 1.53
Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J Med Chem (2005) 1.43
Visualization of the genesis and fate of isotype-switched B cells during a primary immune response. J Exp Med (2003) 1.38
Epigenetic repression of p16(INK4A) by latent Epstein-Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP. PLoS Pathog (2010) 1.27
Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16INK4A and p14ARF expression. Proc Natl Acad Sci U S A (2011) 1.18
Collaboration of Brca1 and Chk2 in tumorigenesis. Genes Dev (2004) 1.18
The AID-induced DNA damage response in chromatin. Mol Cell (2013) 1.04
Induction of p16(INK4a) is the major barrier to proliferation when Epstein-Barr virus (EBV) transforms primary B cells into lymphoblastoid cell lines. PLoS Pathog (2013) 1.01
CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas. Blood (2002) 0.99
Proliferation and differentiation in isogenic populations of peripheral B cells activated by Epstein-Barr virus or T cell-derived mitogens. J Gen Virol (2004) 0.98
A novel human B cell subpopulation representing the initial germinal center population to express AID. Blood (2006) 0.94
A mitotic role for the DNA damage-responsive CHK2 kinase. Nat Cell Biol (2010) 0.84
A minimum of two distinct heritable factors are required to explain correlation structures in proliferating lymphocytes. J R Soc Interface (2010) 0.83